Dr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in Melanoma

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Related Content:

Melanoma

FDA Grants Fast Track Designation to Pembrolizumab Plus Personalized Immunotherapy for Metastatic Melanoma

Omid Hamid, MD, on Trailblazing Research in Melanoma

Adjuvant Pembrolizumab Improves Quality-of-Life Vs Interferon α or Ipilimumab in Resected Melanoma